Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Faran Shimi Naltrexone

    Virtual Booth

    Contact Supplier

    Naltrexone

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Naltrexone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6,879Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Obesity drugs don't make WHO's essential list, but Ebola, MS drugs added
    Obesity drugs don't make WHO's essential list, but Ebola, MS drugs added

    27 Jul 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugs-dont-make-whos-essential-list-ebola-ms-drugs-added-2023-07-26/

    REUTERS
    27 Jul 2023
    Share Share
    Teva's Generic Naltrexone Receives Approval in the U.S.
    Teva's Generic Naltrexone Receives Approval in the U.S.

    06 Jul 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213195

    FDA
    06 Jul 2023
    Share Share
    JanOne files international patent appl. for methods of using low dose naltrexone
    JanOne files international patent appl. for methods of using low dose naltrexone

    28 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/janone-files-international-patent-application-for-methods-of-using-low-dose-naltrexone-to-treat-chronic-pain-301865422.html

    PR NEWSWIRE
    28 Jun 2023
    Share Share
    BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104
    BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104

    13 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/13/2533867/0/en/BioCorRx-Completes-Final-Subject-Enrollment-in-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treatment-of-Opioid-Use-Disorder.html

    GLOBENEWSWIRE
    13 Oct 2022
    Share Share
    Opiant Pharma completes enrollment in phase 2 trial of OPNT002
    Opiant Pharma completes enrollment in phase 2 trial of OPNT002

    08 Oct 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=153707&sid=2

    PHARMABIZ
    08 Oct 2022
    Share Share
    Opiant Announces Completion of Enrollment in Ph 2 Trial of OPNT002, Naltrexone
    Opiant Announces Completion of Enrollment in Ph 2 Trial of OPNT002, Naltrexone

    06 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/06/2529493/0/en/Opiant-Pharmaceuticals-Announces-Completion-of-Enrollment-in-Phase-2-Clinical-Trial-of-OPNT002-Nasal-Naltrexone-in-Patients-with-Alcohol-Use-Disorder.html

    GLOBENEWSWIRE
    06 Oct 2022
    Share Share